| Biomarker ID | 602 |
| PMID | 21367627 |
| Year | 2011 |
| Biomarker | matrix metalloproteinase-9 (MMP-9) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Lymph Node Metastatis |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathway Includes:- Syndecan 1 pathway,Gastrin pathway,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,TWEAK signaling pathway, Endochondral ossification |
| Experiment | Lymph Node Metastatis Posititve Lymph Node Metastatis Negative |
| Type of Biomarker | Prognostic |
| Cohort | 148 CaP patients who underwent radical prostatectomy for clinically localized disease and 10 samples of benign prostatic hyperplasia (BPH) were chosen for the study. Lymph Node Metastatis Posititve(n=10) and Lymph Node Metastatis Negative (n=138) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MMP9 |